<DOC>
	<DOCNO>NCT02561078</DOCNO>
	<brief_summary>The main purpose study evaluate efficacy safety study drug know human regular U-500 insulin ( U-500R ) administer continuous subcutaneous insulin infusion ( CSII ) versus multiple daily injection ( MDI ) participant type 2 diabetes mellitus .</brief_summary>
	<brief_title>An Administration Method Study Human Regular U-500 Insulin ( LY041001 ) Participants With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus ( T2DM ) . Current TDD &gt; 200 ≤600 unit non U500R insulin ( MDI CSII ) and/or U500R MDI syringe vial ≥3 month entry . If TDD U500R insulin combine , insulin U500R exceed 25 % TDD . HbA1c ≥7.5 % ≤12.0 % . Body mass index ≥25 ≤50 kilogram per meter square . Have history stable body weight . Concomitant antihyperglycemic agent ( AHA ) therapy may include metformin ( MET ) , dipeptidyl peptidase4 inhibitor and/or pioglitazone . Approximately 64 96 subject use glucagonlike peptide1 ( GLP1 ) receptor agonist sodiumglucose cotransporter 2 ( SGLT2 ) inhibitor enrol Study Group B . Diagnosed type 1 diabetes mellitus ( T1DM ) type diabetes apart T2DM . Have obvious clinical radiographic sign symptom liver disease ( except nonalcoholic fatty liver disease ) , cirrhosis , acute chronic hepatitis , alanine aminotransferase ( ALT/SGPT ) and/or aspartate aminotransferase ( AST/SGOT ) level ≥2.5X upper limit normal ( ULN ) , alkaline phosphatase ≥2X ULN total bilirubin ≥2X ULN . Have chronic kidney disease Stage 4 high history renal transplantation . Have history 1 episode severe hypoglycemia within 6 month prior screen . Have receive U500R insulin CSII 3 month prior screen . Have blood transfusion severe blood loss within 3 month prior screen know hemoglobinopathy , hemolytic anemia , sickle cell anemia . Are take chronic ( lasting longer 14 consecutive day ) systemic glucocorticoid therapy . Have irregular sleep/wake cycle . Have use weight loss drug 3 month prior screen . Have history bariatric surgery include RouxenY gastric bypass surgery , gastric banding , and/or gastric sleeve . Have history active untreated malignancy , remission clinically significant malignancy last 5 year screen . Significant hearing loss and/or vision impairment deem investigator interfere safe use OmniPod U500 system . Have cardiac disease functional status New York Heart Association ( NYHA ) Class III IV per New York Heart Association Cardiac Disease Functional Classification congestive heart failure require pharmacologic treatment . Are woman breastfeed pregnant , intend become pregnant course study ; men intend impregnate partner ; sexually active procreation potential actively practice birth control method determine investigator medically acceptable . Are investigator site personnel directly affiliate study and/or immediate family . Immediate family define spouse , parent , child , sibling , whether biological legally adopt .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>insulin pump</keyword>
	<keyword>concentrated insulin</keyword>
	<keyword>OmniPod</keyword>
</DOC>